We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$47.1B
AUM Growth
+$2.61B
(+5.9%)
Cap. Flow
-$501M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
14.43%
Holding
3,576
New
705
Increased
706
Reduced
825
Closed
988
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$417M |
| 2 |
Meta Platforms (Facebook)
META
|
+$383M |
| 3 |
Amazon
AMZN
|
+$308M |
| 4 |
Microsoft
MSFT
|
+$293M |
| 5 |
GE Aerospace
GE
|
+$263M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$312M |
| 2 |
Bank of America
BAC
|
+$292M |
| 3 |
ExxonMobil
XOM
|
+$274M |
| 4 |
lululemon athletica
LULU
|
+$238M |
| 5 |
Qualcomm
QCOM
|
+$228M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.05% |
| 2 | Technology | 14.35% |
| 3 | Consumer Discretionary | 13.97% |
| 4 | Financials | 9.9% |
| 5 | Industrials | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Viridian Therapeutics
VRDN
$2.13B
| $16M | 0.03% |
629,320
+17,863
| +3% | +$573K |
|
|
527
CALL
Walmart Inc
WMT
$871B
| $16M | 0.03% |
325,500
-1,047,000
| -76% | -$49.7M |
|
528
Bio-Rad Laboratories Class A
BIO
$8.42B
| $16M | 0.03% |
33,362
+32,767
| +5,507% | +$15.3M |
|
529
PUT
Johnson & Johnson
JNJ
$635B
| $16M | 0.03% |
103,100
-158,400
| -61% | -$25.6M |
|
530
Duke Energy
DUK
$102B
| $15.9M | 0.03% |
165,305
+160,611
| +3,422% | +$15.9M |
|
531
Consolidated Edison
ED
$41.6B
| $15.9M | 0.03% |
166,290
+106,334
| +177% | +$9.96M |
|
532
Microchip Technology
MCHP
$42.8B
| $15.8M | 0.03% |
188,909
-90,151
| -32% | -$7.19M |
|
533
PUT
State Street Industrial Select Sector SPDR ETF
XLI
$33.3B
| $15.8M | 0.03% |
+156,200
| New | +$15.7M |
|
|
TXNM
534
TXNM Energy Inc
TXNM
$6.47B
| $15.8M | 0.03% |
324,188
-1,683
| -0.5% | -$82.6K |
|
|
KVSA
535
DELISTED
Khosla Ventures Acquisition Co. Class A Common Stock
KVSA
| $15.8M | 0.03% |
1,554,651
| – | – |
|
536
PUT
IBM
IBM
$202B
| $15.7M | 0.03% |
+119,900
| New | +$16M |
|
537
Bank of Hawaii
BOH
$3.33B
| $15.7M | 0.03% |
+301,619
| New | +$21.2M |
|
538
Ryanair
RYAAY
$29.5B
| $15.7M | 0.03% |
416,218
+136,343
| +49% | +$5.03M |
|
|
XYZ
539
Block Inc
XYZ
$45.9B
| $15.6M | 0.03% |
+227,271
| New | +$17M |
|
540
Liberty Broadband Class C
LBRDK
$4.15B
| $15.6M | 0.03% |
190,840
-32,571
| -15% | -$2.81M |
|
|
TRTL
541
DELISTED
TortoiseEcofin Acquisition Corp. III
TRTL
| $15.6M | 0.03% |
1,522,643
| – | – |
|
542
CALL
iShares Semiconductor ETF
SOXX
$43.6B
| $15.5M | 0.03% |
104,700
-352,800
| -77% | -$48.1M |
|
543
CALL
VanEck Oil Services ETF
OIH
$2.06B
| $15.5M | 0.03% |
+55,800
| New | +$17.1M |
|
544
Southern Copper
SCCO
$141B
| $15.4M | 0.03% |
218,493
-8,478
| -4% | -$576K |
|
|
FRG
545
DELISTED
Franchise Group, Inc.
FRG
| $15.4M | 0.03% |
565,764
+130,002
| +30% | +$3.74M |
|
546
Tronox
TROX
$995M
| $15.4M | 0.03% |
1,072,014
-353,243
| -25% | -$5.45M |
|
547
Lattice Semiconductor
LSCC
$17.6B
| $15.4M | 0.03% |
161,026
-34,008
| -17% | -$2.8M |
|
|
HES
548
DELISTED
Hess
HES
| $15.3M | 0.03% |
+115,612
| New | +$16.1M |
|
|
AIRJ
549
Montana Technologies Corp
AIRJ
$302M
| $15.2M | 0.03% |
1,485,458
| – | – |
|
550
Invesco
IVZ
$13.3B
| $15.2M | 0.03% |
+926,869
| New | +$16.5M |
|
Similar funds
Marshall Wace's Q1 2023 Portfolio in Review
As of Q1 2023, Marshall Wace held 3,576 positions worth $47.1B, up 5.9% from $44.5B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Marshall Wace's Q1 2023 filing shows 705 new, 706 increased, 825 reduced and 988 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 541,764 shares worth $131M. The largest sale was Cigna, an estimated $312M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- Marshall Wace's largest Q1 2023 buy was Madrigal Pharmaceuticals: 541,764 shares worth $131M.
- Marshall Wace added most to Walmart Inc in Q1 2023, an estimated $417M increase.
- Marshall Wace's biggest Q1 2023 reduction was Cigna, cutting an estimated $312M.
- Marshall Wace fully exited Merck in Q1 2023, selling an estimated $115M.
- Marshall Wace's ten largest holdings make up 14% of its $47.1B portfolio in Q1 2023.
- Marshall Wace opened 705 new positions and closed 988 in Q1 2023.
- Marshall Wace's portfolio value rose 5.9% quarter-over-quarter to $47.1B.
Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.